On March 13, 2019 BioInvent International AB (OMXS: BINV) reported that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance, informing the company that a patent application relevant to its F.I.R.S.T. platform has been allowed and can proceed to grant (Press release, BioInvent, MAR 13, 2019, http://www.bioinvent.com/media/press-releases/releases?id=A2FA3A84867D4C4E [SID1234534288]). The patent is expected to be issued once BioInvent has responded to the Notice. It covers methods for differential biopanning.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This patent, once issued, strengthens the protection in the US for BioInvent’s unique, function-based F.I.R.S.T. platform, which allows for simultaneous identification of clinically relevant target structures and matching antibodies.

The now allowed application is a so called continuation application based on a US patent that was granted in 2013. A similar patent was granted some years earlier by the European patent office, and it is valid in 20 European countries.